NIH Disclosure Of Outside Activities Differs From Pfizer Report, House Cmte. Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
House Commerce Committee identifies 100 instances where drug companies reported consulting arrangements and the National Institutes of Health did not disclose those arrangements. In an effort to place "NIH ethics issues in context," the committee is requesting FDA and 14 other agencies submit lists of outside compensation.